Erasca

Erasca, Inc. is a clinical-stage precision oncology company dedicated to discovering, developing, and commercializing innovative therapies for patients with RAS- and MAPK pathway-driven cancers. The company was founded with a singular mission: to erase cancer by targeting one of the most commonly mutated pathways in cancer—the RAS/MAPK pathway. This pathway is implicated in approximately 5.5 million new cases of cancer each year worldwide, affecting a significant number of patients who currently have limited treatment options.

At Erasca, we pursue a holistic approach to cancer treatment by not only targeting individual nodes within this complex signaling cascade but by also addressing multiple nodes and cooperative mechanisms concurrently. Our comprehensive pipeline is designed to shut down the RAS/MAPK pathway using a modality-agnostic strategy, which encompasses small molecules, large molecules, and protein degraders. With this innovative approach, we aim to create a transformative impact on the lives of patients suffering from a wide range of cancers, thereby bringing hope and the possibility for a cancer-free future.